News | April 25, 2022
Global AYUSH meet ends with promise of Rs 9000 cr. in investment
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Partnership with Modality, award-winning GP super partnership
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Subscribe To Our Newsletter & Stay Updated
